You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer

 

Online download statistics by month:

Online download statistics by month: March 2022 to March 2026

AbstractFullPdf
Mar 2022551568274
Apr 2022275286121
May 2022219221106
Jun 202222323492
Jul 202220521877
Aug 202221922369
Sep 2022235238225
Oct 2022243248102
Nov 202218018359
Dec 202216116063
Jan 202315015063
Feb 202318218278
Mar 202313613790
Apr 202311311386
May 202311611461
Jun 2023989947
Jul 202311811987
Aug 2023979638
Sep 2023939343
Oct 2023797942
Nov 2023989750
Dec 2023858647
Jan 202410310482
Feb 2024767649
Mar 2024717157
Apr 2024979774
May 2024919360
Jun 202410110276
Jul 2024818854
Aug 2024888750
Sep 202410010144
Oct 2024113114182
Nov 202411411654
Dec 20249910350
Jan 202510610745
Feb 202516416555
Mar 202511311580
Apr 202513413478
May 20258687118
Jun 2025626265
Jul 2025110
Sep 2025110
Mar 2026001
Total567757683194